REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pathwork Diagnostics, Inc., a privately held molecular diagnostics company focused on oncology, announced that results of a study evaluating the use of its Pathwork® Tissue of Origin Test in patients with cancer of unknown primary (CUP) were published in the Journal of Molecular Biomarkers and Diagnosis. The Tissue of Origin Test aids in the diagnosis of challenging cancer cases such as those that are metastatic or that have a complex clinical history.
